

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



DC260126

Item No. 19388

CAS Registry No.: 346692-04-4

Formal Name: N-(4-butylphenyl)-4-fluoro-

benzenesulfonamide

MF: C₁₆H₁₈FNO₂S

FW: 307.4 **Purity:** ≥98%

A crystalline solid Supplied as:

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

DC260126 is supplied as a crystalline solid. A stock solution may be made by dissolving the DC260126 in the solvent of choice. DC260126 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of DC260126 in these solvents is approximately 100, 20, and 30 mg/ml, respectively.

DC260126 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, DC260126 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. DC260126 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

DC260126 is a free fatty acid receptor 1 (FFAR1/GPR40) antagonist that inhibits GPR40-mediated Ca²⁺ elevations stimulated by linoleic, oleic, palmitoleic, and lauric acid (Item Nos. 90150, 90260, 10009871, and 10006626, respectively) with IC₅₀ values of 6.28, 5.96, 7.07, and 4.58 μ M, respectively. At 10 mg/kg, it has been shown to inhibit glucose-stimulated insulin secretion, to reduce blood insulin levels, to improve insulin sensitivity, and to decrease the rate of pancreatic β -cell apoptosis in obese diabetic db/db mice.²

References

- 1. Hu, H., He, L., Gong, Z., et al. A novel class of antagonists for the FFAs receptor GPR40. Biochem. Bioph. Res. Commun. 390(3), 557-563 (2009).
- 2. Sun, T., Wang, T., Zhou, Y., et al. DC260126: A small-molecule antagonist of GPR40 that protects against pancreatic β-cells dysfunction in db/db mice. PLoS One 8(6), (2013).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 01/03/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM